vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and LCNB CORP (LCNB). Click either name above to swap in a different company.

LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $14.7M, roughly 1.6× IRIDEX CORP). On growth, LCNB CORP posted the faster year-over-year revenue change (5.1% vs -69.7%). Over the past eight quarters, LCNB CORP's revenue compounded faster (15.7% CAGR vs 11.9%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.

IRIX vs LCNB — Head-to-Head

Bigger by revenue
LCNB
LCNB
1.6× larger
LCNB
$23.9M
$14.7M
IRIX
Growing faster (revenue YoY)
LCNB
LCNB
+74.8% gap
LCNB
5.1%
-69.7%
IRIX
Faster 2-yr revenue CAGR
LCNB
LCNB
Annualised
LCNB
15.7%
11.9%
IRIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
LCNB
LCNB
Revenue
$14.7M
$23.9M
Net Profit
$5.7M
Gross Margin
37.2%
Operating Margin
29.2%
Net Margin
23.7%
Revenue YoY
-69.7%
5.1%
Net Profit YoY
-7.6%
EPS (diluted)
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
LCNB
LCNB
Q4 25
$14.7M
$23.9M
Q3 25
$12.5M
$23.8M
Q2 25
$13.6M
$22.8M
Q1 25
$11.9M
$21.5M
Q4 24
$12.7M
$22.7M
Q3 24
$11.6M
$21.4M
Q2 24
$12.6M
$19.3M
Q1 24
$11.8M
$17.8M
Net Profit
IRIX
IRIX
LCNB
LCNB
Q4 25
$5.7M
Q3 25
$-1.6M
$6.9M
Q2 25
$-994.0K
$5.9M
Q1 25
$-1.7M
$4.6M
Q4 24
$-834.0K
$6.1M
Q3 24
$-1.9M
$4.5M
Q2 24
$-2.7M
$925.0K
Q1 24
$-3.5M
$1.9M
Gross Margin
IRIX
IRIX
LCNB
LCNB
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
LCNB
LCNB
Q4 25
29.2%
Q3 25
-11.3%
35.6%
Q2 25
-6.9%
31.6%
Q1 25
-1.7%
25.6%
Q4 24
-3.9%
32.9%
Q3 24
-16.1%
24.9%
Q2 24
-20.9%
4.9%
Q1 24
-28.0%
12.5%
Net Margin
IRIX
IRIX
LCNB
LCNB
Q4 25
23.7%
Q3 25
-12.6%
29.1%
Q2 25
-7.3%
26.0%
Q1 25
-14.2%
21.4%
Q4 24
-6.6%
27.0%
Q3 24
-16.7%
21.2%
Q2 24
-21.2%
4.8%
Q1 24
-29.5%
10.7%
EPS (diluted)
IRIX
IRIX
LCNB
LCNB
Q4 25
$0.40
Q3 25
$-0.09
$0.49
Q2 25
$-0.06
$0.41
Q1 25
$-0.10
$0.33
Q4 24
$-0.05
$0.44
Q3 24
$-0.12
$0.31
Q2 24
$-0.16
$0.07
Q1 24
$-0.21
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
LCNB
LCNB
Cash + ST InvestmentsLiquidity on hand
$6.0M
$21.6M
Total DebtLower is stronger
$104.4M
Stockholders' EquityBook value
$273.9M
Total Assets
$29.2M
$2.2B
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
LCNB
LCNB
Q4 25
$6.0M
$21.6M
Q3 25
$5.6M
$35.9M
Q2 25
$6.8M
$49.8M
Q1 25
$7.2M
$37.7M
Q4 24
$2.4M
$35.7M
Q3 24
$3.9M
$39.4M
Q2 24
$4.1M
$34.9M
Q1 24
$5.4M
$33.0M
Total Debt
IRIX
IRIX
LCNB
LCNB
Q4 25
$104.4M
Q3 25
$104.7M
Q2 25
$105.0M
Q1 25
$104.6M
Q4 24
$1.0M
$155.2M
Q3 24
$1.4M
$155.7M
Q2 24
$162.2M
Q1 24
$162.6M
Stockholders' Equity
IRIX
IRIX
LCNB
LCNB
Q4 25
$273.9M
Q3 25
$4.7M
$269.9M
Q2 25
$6.1M
$263.5M
Q1 25
$852.0K
$258.7M
Q4 24
$2.1M
$253.0M
Q3 24
$2.6M
$253.2M
Q2 24
$4.2M
$245.2M
Q1 24
$6.5M
$233.7M
Total Assets
IRIX
IRIX
LCNB
LCNB
Q4 25
$29.2M
$2.2B
Q3 25
$28.4M
$2.2B
Q2 25
$31.6M
$2.3B
Q1 25
$34.2M
$2.3B
Q4 24
$29.1M
$2.3B
Q3 24
$30.2M
$2.3B
Q2 24
$31.2M
$2.4B
Q1 24
$34.1M
$2.3B
Debt / Equity
IRIX
IRIX
LCNB
LCNB
Q4 25
0.38×
Q3 25
0.39×
Q2 25
0.40×
Q1 25
0.40×
Q4 24
0.48×
0.61×
Q3 24
0.53×
0.61×
Q2 24
0.66×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
LCNB
LCNB
Operating Cash FlowLast quarter
$34.4M
Free Cash FlowOCF − Capex
$33.4M
FCF MarginFCF / Revenue
140.2%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
6.08×
TTM Free Cash FlowTrailing 4 quarters
$54.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
LCNB
LCNB
Q4 25
$34.4M
Q3 25
$-1.2M
$14.0M
Q2 25
$-397.0K
$5.5M
Q1 25
$-1.1M
$2.2M
Q4 24
$-1.2M
$93.2M
Q3 24
$-3.1M
$11.9M
Q2 24
$-1.3M
$54.9M
Q1 24
$-1.6M
$-11.9M
Free Cash Flow
IRIX
IRIX
LCNB
LCNB
Q4 25
$33.4M
Q3 25
$-1.2M
$13.7M
Q2 25
$-410.0K
$5.2M
Q1 25
$-1.2M
$2.1M
Q4 24
$-1.2M
$89.4M
Q3 24
$-3.1M
$10.5M
Q2 24
$53.8M
Q1 24
$-1.7M
$-12.8M
FCF Margin
IRIX
IRIX
LCNB
LCNB
Q4 25
140.2%
Q3 25
-9.4%
57.4%
Q2 25
-3.0%
23.0%
Q1 25
-9.8%
10.0%
Q4 24
-9.8%
394.0%
Q3 24
-26.5%
49.0%
Q2 24
278.6%
Q1 24
-14.0%
-71.8%
Capex Intensity
IRIX
IRIX
LCNB
LCNB
Q4 25
4.0%
Q3 25
0.1%
1.3%
Q2 25
0.1%
1.0%
Q1 25
0.1%
0.3%
Q4 24
0.1%
16.7%
Q3 24
0.0%
6.7%
Q2 24
0.0%
5.9%
Q1 24
0.0%
4.8%
Cash Conversion
IRIX
IRIX
LCNB
LCNB
Q4 25
6.08×
Q3 25
2.02×
Q2 25
0.92×
Q1 25
0.48×
Q4 24
15.23×
Q3 24
2.63×
Q2 24
59.35×
Q1 24
-6.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons